Neridronic acid - USA

Decision on PGR: Feb 25, 2020

AIA Review	Filing Date	Institution Date	Petitioner	US Patent	Respondent	FINAL WRITTEN DECISION
PGR2018-00092	08/21/2018	02/25/2019	Grunenthal GmbH	9,820,999	Antecip Bioventures II LLC	Some Challenged Claims Unpatentable

US  9,820,999 (ANTECIP BIOVENTURES II LLC; Exp: May 15, 2034): Non-OB

1. A method of treating pain associated with complex regional pain syndrome (CRPS) comprising selecting a human being having CRPS triggered by bone fracture and administering neridronic acid or a pharmaceutically acceptable salt thereof to the human being, wherein the treatment is effective in reducing pain.

Asserted Grounds of Unpatentability:

Claims	35 U.S.C.	Reference(s)/Basis
1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29	102(a)	Varenna 2012
1–4, 9, 10, 12, 14, 16–18, 23–25, 27–29	102(a)	Varenna 2016
1–4, 9, 10, 12, 14, 16–18, 24–25, 27–29	102(a)	Manara
1–4, 9–20, 22–29	103(a)	Varenna 2012, Varenna 2016, Manara, Bruehl Gatti, La Montagna, and Muratore
5–8, 21	103(a)	Varenna 2012, Varenna 2016, Manara, and Manicourt
30	103(a)	Varenna 2012, Varenna 2016 Manara, Schwarzer, Bruehl, Gatti, La Montagna, and Muratore
1–30	112(a), Enablement

Order:

It is ORDERED that claims 1–4, 9, 10, 12, 14, 16–18, 23–25, and 27–29 of the ’999 patent are unpatentable;

FURTHER ORDERED that claims 5–8, 11, 13, 15, 19–22, 26, and 30 of the ’999 patent are not shown to be unpatentable.